ABVC BIOPHARMA, INC. (ABVC): Nasdaq/NYSE listing notice — ABVC BioPharma regains Nasdaq minimum bid price compliance; reports 234% revenue growth in FY2024

ABVC BIOPHARMA, INC.

Regained compliance after maintaining $1.00 bid price for 10 consecutive days through May 12, 2025.
FY2024 revenue increased 234% YoY; operating expenses reduced 21%; EPS improved 77%.
Secured three licensing partnerships with potential $7M upfront and up to $660M in milestones.
Received approximately $0.5M in upfront payments in FY2025 year-to-date.
Preliminary discussions underway with pharma and AI firms for co-developing Phase III-ready MDD and ADHD candidates.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 13, 2025, the Company received a notification letter (the “ Notification Letter ”) from Nasdaq notifying the Company that the Staff has determined that the Company has met the Bid Requirement and therefore the matter is closed. Accordingly, no reverse stock split is necessary at this time.

View on SEC.gov

Browse all listing & compliance notices →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-042982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.